Amgen Dazodalibep Phase 3 OASIZ-301 Results Show Systemic Disease Activity Gains in Sjögren’s Disease
Amgen announced Phase 3 OASIZ-301 results for dazodalibep in Sjögren’s disease on November 11, 2026. Both dosing regimens met the primary ESSDAI endpoint at Week 48, and full data will go to ACR Convergence 2026.
